R&D Pipeline

Phase:

Therapy:

Pipeline last updated 1 May 2014
Compound/indication Phase 1 Phase 2 Phase 3 Filed
Anti-IL20 (NN8226)

Inflammation - Rheumatoid arthritis
Anti-IL21 (NN8828)

Inflammation - Crohn's disease
Anti-NKG2D (NN8555)

Inflammation - Crohn's disease
Anti-IL21 (NN8828)

Inflammation - Systemic lupus erythematosus
Anti-C5aR-215 (NN8210)

Inflammation - Rheumatoid arthritis
  •